Ronawk develops a T-Block technology to produce patient-specific biologics to treat diseases, cancer, organ injuries, and burns by enabling mass production of patient stem cells. The company's proprietary technology provides a break-through method to grow primary stem cells in a 3D environment while maintaining stem cell characteristics of the cell population outside of the body. Its technology enables rapid expansion of stem cells that could be used for early-stage diagnostics or in repairing injured tissues. Ronawk was founded in 2019 and is headquartered in Olathe, Kansas.
Partial Data by Infogroup (c) 2024. All rights reserved.